Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Bone Marrow Transplantation

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors

Leukemia volume 19, pages 1613–1620 (2005)Cite this article

Abstract

We report long-term outcome in 102 patients with cCML transplanted from an HLA-identical sibling donor from 1982 to 1998. The conditioning regimen was based on cyclophosphamide associated with either total body irradiation (TBI) (37 patients) or with busulfan (63 patients). Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporin and methotrexate in the majority of the patients. Fifteen year overall survival was estimated at 53% (95% confidence interval (CI), 44–65) with a plateau after 2.5 years. Long-term survival was adversely affected by: longer time from chronic myeloid leukemia (CML) diagnosis to transplantation, older age at time of transplantation and GvHD (acute grade III–IV or chronic extensive). The main cause of death was infection, related to GvHD in 69% of patients. Splenectomy also significantly increased the risk of bacterial infection. 15-year relapse was estimated at 8% (95% CI, 0.1–14). Late malignancies occurred in seven patients, four of whom had an invasive cancer. Other frequent late complications included cataracts, psychological depression, osteonecrosis and hypothyroidism. These complications were more frequent following splenectomy, TBI and in patients with chronic extensive GvHD. We conclude that allogeneic transplantation with a related donor can cure more than half of CML patients in chronic phase, although physicians should be alert to long-term complications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31–35.

    Article  CAS  Google Scholar 

  2. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536.

    CAS  PubMed  Google Scholar 

  3. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.

    Article  CAS  Google Scholar 

  4. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553–560.

    Article  CAS  Google Scholar 

  5. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081.

    Article  CAS  Google Scholar 

  6. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064–4077.

    CAS  PubMed  Google Scholar 

  7. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  8. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU . Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069.

    Article  CAS  Google Scholar 

  9. Guilbert-Douet N, Morel F, Le Bris MJ, Berthou C, Morice P, Bourquard P et al. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. Leukemia 2004; 18: 1140–1142.

    Article  CAS  Google Scholar 

  10. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  Google Scholar 

  11. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  13. Kaplan ES, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  14. Gray RJ . Spline-based tests in survival analysis. Biometrics 1994; 50: 640–652.

    Article  CAS  Google Scholar 

  15. Cox D . Regression models and life tables. J R Stat Soc 1972; 34: 187–220.

    Google Scholar 

  16. Devergie A, Reiffers J, Vernant JP, Herve P, Guyotat D, Maraninchi D et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379–386.

    CAS  PubMed  Google Scholar 

  17. Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Bone Marrow Transplant 1994; 13: 197–201.

    CAS  PubMed  Google Scholar 

  18. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981–2990.

    CAS  PubMed  Google Scholar 

  19. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  PubMed  Google Scholar 

  20. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401.

    CAS  PubMed  Google Scholar 

  21. Aschan J, Ringden O, Sundberg B, Klaesson S, Ljungman P, Lonnqvist B . Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 1993; 50: 269–274.

    Article  CAS  Google Scholar 

  22. Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960–3962.

    CAS  PubMed  Google Scholar 

  23. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263–2268.

    CAS  PubMed  Google Scholar 

  24. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10: 5065–5071.

    Article  CAS  Google Scholar 

  25. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  Google Scholar 

  26. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  Google Scholar 

  27. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.

    Article  CAS  Google Scholar 

  28. Koh LP, Hwang WY, Tan CH, Linn YC, Goh YT, Chuah CT et al. Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling-evaluation of risks and benefits. Ann Hematol 2004; 83: 286–294.

    Article  CAS  Google Scholar 

  29. Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002; 117: 444–450.

    Article  Google Scholar 

  30. Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683–3686.

    CAS  PubMed  Google Scholar 

  31. Ribaud P, Chastang C, Latge JP, Baffroy-Lafitte L, Parquet N, Devergie A et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–330.

    Article  CAS  Google Scholar 

  32. Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726–2733.

    Article  CAS  Google Scholar 

  33. Kalhs P, Schwarzinger I, Anderson G, Mori M, Clift RA, Storb R et al. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86: 2028–2032.

    CAS  PubMed  Google Scholar 

  34. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.

    Article  CAS  Google Scholar 

  35. Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint MT, Esperou H et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999; 93: 4109–4115.

    CAS  PubMed  Google Scholar 

  36. Zierhut D, Lohr F, Schraube P, Huber P, Wenz F, Haas R et al. Cataract incidence after total-body irradiation. Int J Radiat Oncol Biol Phys 2000; 46: 131–135.

    Article  CAS  Google Scholar 

  37. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.

    CAS  PubMed  Google Scholar 

  38. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant Proc 1994; 26: 1831–1832.

    CAS  PubMed  Google Scholar 

  39. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB et al. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004; 27: 73–80.

    Article  CAS  Google Scholar 

  40. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. M Robin and P Guardiola: Both these authors contributed equally to this work and both should be considered as first author

Authors and Affiliations

  1. Service d'hématologie – greffe de moelle, Hôpital Saint-Louis, APHP, Paris, France

    M Robin, P Guardiola, A Devergie, M Yeshurun, S Shapiro, H Esperou, P Ribaud, V Rocha, E Gluckman & G Socié

Authors
  1. M Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Guardiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Devergie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Yeshurun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Esperou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Ribaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Gluckman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Socié.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robin, M., Guardiola, P., Devergie, A. et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19, 1613–1620 (2005). https://doi.org/10.1038/sj.leu.2403821

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403821

Keywords

This article is cited by

Search

Advanced search

Quick links